Javid J. Moslehi
-
- Chemotherapy-induced cardiotoxicity and mitigation 57
- Oncology top 0.2%
- Cancer Immunotherapy and Biomarkers 40
- CAR-T cell therapy research 24
- Peptidase Inhibition and Analysis 17
- Cancer Treatment and Pharmacology 16
- Geriatrics and Gerontology top 0.5%
- Aging top 1%
- Hematology top 0.5%
- Chronic Myeloid Leukemia Treatments 16
-
- Chronic Lymphocytic Leukemia Research 19
-
- Cardiac Imaging and Diagnostics 15
- Co-authors
- Douglas B. JohnsonJoe‐Elie SalemJustin M. BalkoBénédicte Lebrun‐VignesMichael W. DeiningerCaroline A. NebhanJohn D. GroarkeAli Manouchehri
- Journals
- Circulation (21 papers)Journal of the American College of Cardiology (11 papers)Journal of Clinical Oncology (10 papers)
- Partner nations
- United StatesFranceItaly
In The Last Decade
Javid J. Moslehi
201 papers receiving 15.8k citations
Hit Papers
Peers
Comparison fields: 5 of 145
- Cardiology and Cardiovascular Medicine 6.4k
- Oncology 6.6k
- Geriatrics and Gerontology 471
- Aging 184
- Hematology 1.2k
Countries citing papers authored by Javid J. Moslehi
This map shows the geographic impact of Javid J. Moslehi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Javid J. Moslehi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Javid J. Moslehi more than expected).
Fields of papers citing papers by Javid J. Moslehi
This network shows the impact of papers produced by Javid J. Moslehi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Javid J. Moslehi. The network helps show where Javid J. Moslehi may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Javid J. Moslehi, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2026 | 1 | |
| 2 | 2025 | 0 | |
| 3 | 2025 | 5 | |
| 4 | Clinical spectrum and evolution of immune-checkpoint inhibitors toxicities over a decade—a worldwide perspectivebreakdown → | 2024 | 67 |
| 5 | 2024 | 0 | |
| 6 | 2024 | 15 | |
| 7 | 2023 | 9 | |
| 8 | 2023 | 10 | |
| 9 | 2022 | 48 | |
| 10 | 2022 | 11 | |
| 11 | 2021 | 49 | |
| 12 | 2020 | 42 | |
| 13 | 2020 | 161 | |
| 14 | 2020 | 45 | |
| 15 | 2019 | 115 | |
| 16 | 2019 | 35 | |
| 17 | Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance studybreakdown → | 2019 | 260 |
| 18 | 2018 | 21 | |
| 19 | 2017 | 12 | |
| 20 | 2017 | 287 |
About Javid J. Moslehi
Javid J. Moslehi is a scholar working on Cardiology and Cardiovascular Medicine, Oncology and Hematology, having authored 211 papers that have together received 16.0k indexed citations. Recurring topics across this work include Chemotherapy-induced cardiotoxicity and mitigation (57 papers), Cancer Immunotherapy and Biomarkers (40 papers), CAR-T cell therapy research (24 papers), Chronic Lymphocytic Leukemia Research (19 papers), Peptidase Inhibition and Analysis (17 papers), Cancer Treatment and Pharmacology (16 papers), Chronic Myeloid Leukemia Treatments (16 papers) and Cardiac Imaging and Diagnostics (15 papers). The work is most often cited by research in Cardiology and Cardiovascular Medicine (6.4k citations), Oncology (6.6k citations) and Geriatrics and Gerontology (471 citations). Javid J. Moslehi has collaborated with scholars based in United States, France and Italy. Frequent co-authors include Douglas B. Johnson, Joe‐Elie Salem, Justin M. Balko, Bénédicte Lebrun‐Vignes, Michael W. Deininger, Caroline A. Nebhan, John D. Groarke, Ali Manouchehri, Douglas B. Johnson and William G. Kaelin. Their work appears in journals such as Circulation, Journal of the American College of Cardiology, Journal of Clinical Oncology, Blood and Circulation Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.